Sugi Predict

Sugi Predict / Compounds / SCHEMBL1361426

SCHEMBL1361426

SCHEMBL1361426

O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1)Oc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 16/20 1.00
▸ EGFR P00533 14/20 1.00
▸ ERBB2 P04626 13/20 1.00
▸ LCK P06239 6/20 0.78
▸ KDR P35968 6/20 0.78
▸ STK3 Q13188 6/20 0.78
▸ MAP4K5 Q9Y4K4 6/20 0.78
▸ AURKB Q96GD4 5/20 0.78
▸ RET P07949 4/20 0.78
▸ FGFR1 P11362 4/20 0.78
▸ TAOK1 Q7L7X3 4/20 0.78
▸ MAP4K4 O95819 3/20 0.78
▸ FYN P06241 3/20 0.78
▸ FLT1 P17948 3/20 0.78
▸ AURKA O14965 2/20 0.78
▸ PRKD3 O94806 2/20 0.78
▸ INSR P06213 2/20 0.78
▸ LYN P07948 2/20 0.78
▸ FLT4 P35916 2/20 0.78
▸ FRK P42685 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1363333 0.94 IGF1R (0.89) IGF1REGFRERBB2LCKKDR
SCHEMBL1363423 0.91 IGF1R (1.00) IGF1REGFRERBB2LCKKDR
SCHEMBL1362619 0.90 IGF1R (0.82) IGF1REGFRERBB2LCKKDR
SCHEMBL1362054 0.90 IGF1R (1.00) IGF1REGFRERBB2LCKKDR
SCHEMBL1361415 0.89 IGF1R (0.79) IGF1REGFRERBB2LCKKDR
SCHEMBL1362815 0.88 PTK2 (0.86) IGF1REGFRERBB2LCKKDR
SCHEMBL1362751 0.88 IGF1R (0.89) IGF1REGFRERBB2LCKKDR
SCHEMBL1361835 0.88 IGF1R (1.00) IGF1REGFRERBB2LCKKDR
SCHEMBL1363675 0.88 EGFR (0.85) IGF1REGFRERBB2LCKKDR
SCHEMBL1362417 0.87 IGF1R (0.82) IGF1REGFRERBB2LCKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 — — US claimed
US-7737184-B2 Histone deacetylase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-06-15 — — US claimed
US-20080033015-A1 Histone Deacetylase Inhibitors MERCK SHARP & DOHME LLC 2008-02-07 — — US claimed
EP-1773761-A1 HISTONE DEACETYLASE INHIBITORS Merck & Co., Inc. (US) 2007-04-18 — — EP claimed
WO-2006017216-A1 HISTONE DEACETYLASE INHIBITORS MERCK & CO., INC. (US) 2006-02-16 — — WO claimed
US-20230094176-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2023-03-30 — — US disclosed
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 — — US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
EP-2683371-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS Cereno Scientific AB (SE) 2014-01-15 — — EP disclosed
WO-2012120262-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS LARSSON PIA (SE) 2012-09-13 — — WO disclosed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 — — US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 — — EP disclosed
US-7737184-B2 Histone deacetylase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-06-15 — — US disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 — — WO disclosed
US-20080033015-A1 Histone Deacetylase Inhibitors MERCK SHARP & DOHME LLC 2008-02-07 — — US disclosed
EP-1773761-A1 HISTONE DEACETYLASE INHIBITORS Merck & Co., Inc. (US) 2007-04-18 — — EP disclosed
WO-2006017216-A1 HISTONE DEACETYLASE INHIBITORS MERCK & CO., INC. (US) 2006-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 IGF1R 4604/4885EGFR 4689/4885ERBB2 4838/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 IGF1R 4604/4885EGFR 4689/4885ERBB2 4838/4885
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 IGF1R 4604/4885EGFR 4689/4885ERBB2 4838/4885
US-20230094176-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC2, HDAC1 IGF1R 4565/4885EGFR 4746/4885ERBB2 4842/4885
US-20080033015-A1 Histone Deacetylase Inhibitors HDAC1, HDAC5, HDAC9 IGF1R 1444/4885EGFR 574/4885ERBB2 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.